The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Mercury Biopharmaceutical's current ratio for the quarter that ended in Dec. 2024 was 12.63.
Mercury Biopharmaceutical has a current ratio of 12.63. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Mercury Biopharmaceutical's Current Ratio or its related term are showing as below:
ROCO:6932'
s Current Ratio Range Over the Past 10 Years
Min: 0.32 Med: 7.47 Max: 42.21
Current: 12.63
During the past 6 years, Mercury Biopharmaceutical's highest Current Ratio was 42.21. The lowest was 0.32. And the median was 7.47.
ROCO:6932's Current Ratio is ranked better than 95.68% of 1018
companies
in the Drug Manufacturers industry
Industry Median: 1.98
vs ROCO:6932: 12.63
Mercury Biopharmaceutical Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Mercury Biopharmaceutical's Current Ratio
For the Drug Manufacturers - Specialty & Generic subindustry, Mercury Biopharmaceutical's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mercury Biopharmaceutical's Current Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mercury Biopharmaceutical's Current Ratio distribution charts can be found below:
* The bar in red indicates where Mercury Biopharmaceutical's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mercury Biopharmaceutical (ROCO:6932) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Mercury Biopharmaceutical Current Ratio Related Terms
Thank you for viewing the detailed overview of Mercury Biopharmaceutical's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Mercury Biopharmaceutical Corp focuses on the development of drugs for unmet medical needs. It offers a development platform focusing on rapid release and free adjustable doses. Its 3D powder bonding method (binder jetting) combines powder and special molding adhesive and stacks them in layers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ROCO:6932 has been successfully added to your 